课题基金 / 基金详情

CYSTEAMINE BITARTRATE DELAYED-RELESEASE CAPSULES (RP103) COMPARED TO CYSTEAMINE

CYSTEAMINE BITARTRATE DELAYED-RELESEASE CAPSULES (RP103) COMPARED TO CYSTEAMINE
半胱胺酒石酸氢盐延迟释放胶囊 (RP103) 与半胱胺相比
批准号：
8166878
负责人：
BRUCE A BARSHOP
金额：
$1.95万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN DIEGO
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
项目状态：
已结题
起止时间：
2009-12-01 至 2010-06-30
来源：
https://reporter.nih.gov/project-details/8166878
关键词：
AssesComputer Retrieval of Information on Scientific Projects DatabaseCystagonCysteamineCystinosisEnrollmentFundingGrantInstitutionPatientsResearchResearch PersonnelResourcesSafetySourceUnited States National Institutes of Healthcapsuledesign

项目摘要

项目成果

BRUCE A BARSHOP的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Asses the PK, PD, safety and tolerability of RP103 compared to Cystagon in patients with nephropathic cystinosis. Patients taking Cystagon as part of their treatment for cystinosis will be enrolled into the study and results will be used to inform the design the confirmatory PK and pivotal PD study comparing RP103 to Cystagon.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CLINICAL TRIAL: A PHASE II STUDY OF PN401 PYRIMIDINE RESPONSIVE SYNDROME OF NEUR
CLINICAL TRIAL: ALGLUCOSIDASE ALFA TEMPORARY ACCESS PROGRAM (ATAP) PROTOCOL AGLU
CLINICAL TRIAL: A PHASE II STUDY OF PN401 PYRIMIDINE RESPONSIVE SYNDROME OF NEUR
CLINICAL TRIAL: MYOZYME? TEMPORARY ACCESS PROGRAM (MTAP)